The research report on hepatocellular carcinoma drugs market segments the global market by drug class, (PD-1/PD-L1 Inhibitors, and Tyrosine Kinase Inhibitors), by end user, and geography
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that arises from the liver cells or hepatocytes. The disease is found to occur mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of hepatocellular carcinoma is mainly done by imaging tests such as ultrasound, MRI, CT scan, and liver biopsy. Treatment for hepatocellular carcinoma mainly includes radiation therapy, ablation therapy in addition to chemotherapy and targeted drug therapy.
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1596
A majority of the HCC patients are diagnosed at the end-stage of liver dysfunction. Due to poor prognosis of the condition, mortality rate is approximately the same as the incidence rate. Therefore, early detection of the cancer is an important parameter to improve the survival of affected patients, thus aiding in growth of the global hepatocellular carcinoma drugs market.
Increasing incidence of global hepatocellular carcinoma cases is a major factor augmenting market growth. According to the research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Also, according to the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) accounted to 854,000 new cases of liver cancer and 810,000 related deaths in 2015. Furthermore, increasing incidence and mortality of hepatocellular carcinoma is attributed to the emergence of new risk factors such as hepatitis B and C viral infections, metabolic disorders such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as alcohol and aflatoxin.
Click To Continue Reading on Hepatocellular Carcinoma Drugs Market
Contact Us:
Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: sales@coherentmarketinsights.com
Visit our news Website: https://www.coherenttimes.org/
Aspergillosis Treatment Market Opportunity Analysis, 2018-2026
Patent expiration of branded products and drug resistance to antifungal medications are the factors restraining growth of the market.
Measles Mumps and Rubella (MMR) Vaccines Market Opportunity Analysis, 2018 – 2026
Vaccine manufacturers are focusing on partnering with organizations such WHO, UNICEF, and GAVI Alliance to improve their vaccination programs, in order to reach the maximum population to offer vaccines.
PoC Platform & Technology Market to Surpass US$ 45.4 Billion by 2025
The global POC platform & technology market was valued at US$ 21,370.3 Million in 2016 and is expected to exhibit a robust CAGR of 8.9% over the forecast period (2017 – 2025).
